Home | Business News | Browse by Publication | B | Biotech Week

Lantheus Medical Imaging, Inc. to Receive LEU-Derived Mo-99 From Australian Nuclear Science and Technology Organisation ANSTO and Becomes First to Supply U.S. Market.

Article Excerpt
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, has finalized an arrangement with the Australian Nuclear Science and Technology Organisation (ANSTO) to receive molybdenum-99 (Mo-99) produced from low-enriched uranium (LEU) targets in ANSTO's new OPAL reactor. This supply arrangement positions Lantheus to be the first company to supply technetium-99m (Tc-99m) derived from LEU to the U.S. market and demonstrates the Company's commitment to ensuring reliable supply and global access to Tc-99m, the medical isotope used in approximately 80 percent of all nuclear medicine procedures (see also Lantheus Medical Imaging, Inc.).

Lantheus will soon receive a supply of Mo-99 at regular intervals from ANSTO, for use in its TechneLite® generator line that is currently distributed to the U.S. and Canadian markets. ANSTO has secured the necessary regulatory approval from the Therapeutic Goods Administration (TGA) in Australia to use the LEU Mo-99 in a Tc-99m generator. The LEU-derived Mo-99 from ANSTO has been tested and validated by Lantheus for use in its TechneLite® generator line to ensure the consistency...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!